These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 24945890)

  • 1. Multiple primary cancers as a guide to heritability.
    Cybulski C; Nazarali S; Narod SA
    Int J Cancer; 2014 Oct; 135(8):1756-63. PubMed ID: 24945890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beyond BRCA1 and BRCA2.
    King-Spohn K; Pilarski R
    Curr Probl Cancer; 2014; 38(6):235-48. PubMed ID: 25497410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A molecular genetic and statistical approach for the diagnosis of dual-site cancers.
    Brinkmann D; Ryan A; Ayhan A; McCluggage WG; Feakins R; Santibanez-Koref MF; Mein CA; Gayther SA; Jacobs IJ
    J Natl Cancer Inst; 2004 Oct; 96(19):1441-6. PubMed ID: 15467033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic alterations and MSI status in primary, synchronous, and metachronous tumors in a family with hereditary nonpolyposis colorectal cancer (HNPCC).
    González-Aguilera JJ; Nejda N; Fernández FJ; Medina V; González-Hermoso F; Barrios Y; Moreno Azcoita M; Fernández-Peralta AM
    Am J Clin Oncol; 2003 Aug; 26(4):386-91. PubMed ID: 12902892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of BRCA1/2 mutations in sporadic breast/ovarian cancer patients and identification of a novel de novo BRCA1 mutation in a patient diagnosed with late onset breast and ovarian cancer: implications for genetic testing.
    De Leeneer K; Coene I; Crombez B; Simkens J; Van den Broecke R; Bols A; Stragier B; Vanhoutte I; De Paepe A; Poppe B; Claes K
    Breast Cancer Res Treat; 2012 Feb; 132(1):87-95. PubMed ID: 21553119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population-based screening for hereditary breast cancer in a region of North-Central Italy.
    Casadei S; Falcini F; Naldoni C; Amadori D; Calistri D
    Int J Mol Med; 2002 Sep; 10(3):299-305. PubMed ID: 12165804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Scoping the family history: assessment of Lynch syndrome (hereditary nonpolyposis colorectal cancer) in primary care settings--a primer for nurse practitioners.
    Maradiegue A; Jasperson K; Edwards QT; Lowstuter K; Weitzel J
    J Am Acad Nurse Pract; 2008 Feb; 20(2):76-84. PubMed ID: 18271762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hereditary breast-ovarian cancer: clinical findings and medical management.
    Marshall M; Solomon S
    Plast Surg Nurs; 2007; 27(3):124-7. PubMed ID: 17901820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical features of ovarian cancer in hereditary nonpolyposis colorectal cancer.
    Watson P; Bützow R; Lynch HT; Mecklin JP; Järvinen HJ; Vasen HF; Madlensky L; Fidalgo P; Bernstein I;
    Gynecol Oncol; 2001 Aug; 82(2):223-8. PubMed ID: 11531271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Genetic counseling in familial breast cancer].
    Pichert G
    Ther Umsch; 2008 Apr; 65(4):235-41. PubMed ID: 18622917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GSTM1, GSTT1 and GSTP1 in patients with multiple breast cancers and breast cancer in association with another type of cancer.
    Chirilă DN; Bălăcescu O; Popp R; Oprea A; Constantea NA; Vesa S; Ciuce C
    Chirurgia (Bucur); 2014; 109(5):626-33. PubMed ID: 25375048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular genetics and management strategies in hereditary cancer syndromes.
    Hanna NN; Mentzer RM
    J Ky Med Assoc; 2003 Mar; 101(3):100-7. PubMed ID: 12674901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hereditary predisposition for cancer of the breast and the ovary].
    Lalle P; Stoppa-Lyonnet D; Mazoyer S; Rio P; Girodet C; Hardouin A; Narod SA; Sobol H; Bignon YJ
    Bull Cancer; 1993 Oct; 80(10):857-65. PubMed ID: 8204923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic testing and prevention of hereditary cancer at the MMCI--over 10 years of experience.
    Foretova L; Petrakova K; Palacova M; Kalabova R; Svoboda M; Navratilova M; Schneiderova M; Bolcak K; Krejci E; Drazan L; Mikova M; Hazova J; Vasickova P; Machackova E
    Klin Onkol; 2010; 23(6):388-400. PubMed ID: 21348412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations of the P53 tumor suppressor gene as clonal marker for multiple primary lung cancers.
    Mitsudomi T; Yatabe Y; Koshikawa T; Hatooka S; Shinoda M; Suyama M; Sugiura T; Ogawa M; Takahashi T
    J Thorac Cardiovasc Surg; 1997 Sep; 114(3):354-60. PubMed ID: 9305187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRCA1 and BRCA2 mutations in breast cancer families with multiple primary cancers.
    Shih HA; Nathanson KL; Seal S; Collins N; Stratton MR; Rebbeck TR; Weber BL
    Clin Cancer Res; 2000 Nov; 6(11):4259-64. PubMed ID: 11106241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic testing by cancer site: ovary.
    Weissman SM; Weiss SM; Newlin AC
    Cancer J; 2012; 18(4):320-7. PubMed ID: 22846732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular profiling of synchronous and metachronous cancers of the pancreas reveal molecular mimicry between samples from the same patient.
    Talbott VA; Yeo CJ; Brody JR; Witkiewicz AK
    J Surg Res; 2012 Jul; 176(1):154-8. PubMed ID: 22118834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 12-year experience at a tertiary hospital on patients with multiple primary malignant neoplasms.
    Papaconstantinou I; Mantzos DS; Asimakoula K; Michalaki V; Kondi-Pafiti A
    J BUON; 2015; 20(1):332-7. PubMed ID: 25778335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.